Preserve the US interchangeable standard that has helped drive physician and patient confidence in biosimilars

Author byline as per print journal: Michael S Reilly, Esq Abstract: The US FDA proposed eliminating the distinction between biosimilars and interchangeable biosimilars, aiming to align with European policy and… Read More »